PDCD1 and neoplasm: The anti-PD-L1, clone SP142, and anti-PD-1 clone NAT105 were used, and PD-L1 and PD-1 were evaluated as the percentage area of positive staining within tumor-infiltrating lymphocytes (TILs) (Table 2).